Polygon Labs CEO Marc Boiron stated that stablecoins will significantly enhance the efficiency of capital utilization, reducing capital idling caused by pre-funded accounts, settlement delays, bank outages, and idle balances. This will allow businesses and consumers to have more funds available for spending. He pointed out that with improved capital efficiency, the same dollar can support more purchases, inventory, payroll, and cross-border trade, and the next round of payment winners will be companies capable of achieving millisecond-level payments.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.




Expanded U.S. Treasury long-bond buybacks helped pull yields lower and supported a modest rebound in risk appetite, with the major indexes closing slightly higher. At the same time, Bitcoin briefly rose above $70,000 and lifted crypto-linked equities, while positive Phase 3 vaccine data from Merck and Moderna pushed healthcare and biotech stocks higher. SK Hynix’s large-scale buyback also kept attention on the storage cycle and AI-related demand. Markets are continuing to digest the relatively hawkish Fed minutes while positioning ahead of earnings from Alibaba and Walmart.



Bitcoin and Ethereum surged in a historic 24-hour rally that added $190 billion to the crypto market and triggered $2.98 billion in liquidations. Here's what Treasury buybacks, a massive short squeeze, and new SEC rules mean for traders on WEEX.


















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.





Expanded U.S. Treasury long-bond buybacks helped pull yields lower and supported a modest rebound in risk appetite, with the major indexes closing slightly higher. At the same time, Bitcoin briefly rose above $70,000 and lifted crypto-linked equities, while positive Phase 3 vaccine data from Merck and Moderna pushed healthcare and biotech stocks higher. SK Hynix’s large-scale buyback also kept attention on the storage cycle and AI-related demand. Markets are continuing to digest the relatively hawkish Fed minutes while positioning ahead of earnings from Alibaba and Walmart.